Drug Farm, a Shangai, China- and Guilford, MA-based biotechnology company utilizing genetics and AI technologies to discover and develop innovative, immune-modulating therapies, completed financing totaling $56m USD.
Backers included BioVeda China Fund (BVCF), WuXi AppTec’s corporate venture fund, South China Venture Capital (SCVC), Detong Capital, and Zhejiang United Investment Group (ZUIG).
The company intends to use the funds to initiate human clinical trials with its lead drug DF-006, an orally bioavailable drug for hepatitis B virus (HBV) infection and other liver diseases and to further advance its additional pipeline candidates for therapies in cancer and autoimmune diseases.
Led by Dr. Tian Xu, founder and Chairman, and Dr. Henri Lichenstein, CEO and Board Member, Drug Farm is a biotech developing innovative treatments targeting innate immunity for HBV, cancer, and autoimmune diseases. Its IDInVivo platform combines technologies in genetics and AI to discover new treatments. IDInVivo technology allows the direct assessment of gene targets in living animals with intact immune systems. Using the IDInVivo platform, Drug Farm has identified novel innate immunity pathways and targets and is now rapidly advancing multiple first-in-class drug candidates into clinical development.